• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Genetic targets help alcohol addiction, study finds


Alcoholics who are tested for genotype specificity prior to receiving ondansetron may have significantly improved outcomes, according to new research.

Key Points

Alcoholics who are tested for genotype specificity prior to receiving ondansetron may have significantly improved outcomes, according to a report published in the March 2011 issue of American Journal of Psychiatry.

In a double-blind controlled trial, a cohort of 283 people with alcohol addiction were randomized by their specific genotype of the serotonin transporter gene: the 5'-regulatory region of the 5-HTT gene (LL/LS/SS) and a polymorphism in the 3'-untranslated region. Study subjects were given either ondansetron (4 μg/kg twice daily) or placebo for 11 weeks, and also received cognitive behavioral therapy. People with the LL genotype who received ondansetron reported a lower mean number of drinks per drinking day (-1.62) and a higher percentage of days abstinent (11.27%) than participants who received placebo. Individuals with non-LL genotype patterns receiving ondansetron responded less favorably than the LL group.

Results from this investigation demonstrate the direct relationship of an alcohol addiction patient's genetic profile and his/her ability to respond to therapy. Based on the results of their study, investigators "propose a new pharmacogenetic approach using ondansetron to treat severe drinking and improve abstinence in alcoholics."

"One side of targeting treatment is tailoring the efficacy of response, that is, giving medicine to people who respond to the medication. The other side of this approach is to have no side effects and no adverse events," said Dr Johnson.

From a payer perspective, Dr Johnson said, "Even if you look at the most successful psychiatric drugs, not much more than half of the people taking a medicine, sometimes less than that, respond to it. This is a huge waste in medical costs, hospital costs, drug expense, and it doesn't help patients."


Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry. 2011;168:265–275.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.